Cephalexin Anhydrous
The anhydrous form of cephalexin is a first-generation oral cephalosporin equivalent in antibacterial activity to the standard formulation. It is used for common bacterial infections including skin, urinary, and respiratory infections caused by susceptible organisms. The anhydrous form simply lacks the water of crystallization present in some preparations.
Peso molecular
347,4000 g/mol
LogP
0,60
TPSA
138,00 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
InChI
InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
Molecular Formula
C16H17N3O4S
HBD / HBA
3 / 6
Enlaces Rotables
4
Átomos Pesados
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The anhydrous form of cephalexin is a first-generation oral cephalosporin equivalent in antibacterial activity to the standard formulation. It is used for common bacterial infections including skin, urinary, and respiratory infections caused by susceptible organisms. The anhydrous form simply lacks the water of crystallization present in some preparations.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cephalexin Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1727. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 27447. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cephalexin-anhydrous"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cephalexin-anhydrous/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cephalexin-anhydrous/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cephalexin-anhydrous/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cephalexin-anhydrous"></drugfyi-drug>